Stock Analysis
Halozyme Therapeutics, Inc. (HALO) Stock Analysis
Halozyme Therapeutics, Inc. (HALO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Halozyme Therapeutics, Inc. (HALO) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 84/100. Risk is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
HALO at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $100.27 |
| AIQ Score | 78/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $12.56B |
| P/E Ratio (TTM) | 23.87 |
| Forward P/E | — |
| EPS (latest quarter) | — |
| Revenue (latest quarter) | — |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.58 |
| Volume | 2.28M |
| 52-week range | $61.23-$134.00 |
| RSI 14 | 26.68 |
| 50-Day SMA | $114.56 |
| 200-Day SMA | $85.43 |
| Analyst Price Target | — |
| Next Earnings | — |
HALOHalozyme Therapeutics, Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum84
- Value76
- Quality81
- Risk resilience63
- Sentiment—
HALO Stock Analysis Summary
Halozyme Therapeutics, Inc. (HALO) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 84/100. Risk resilience is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, HALO has AIQ Score of 78/100 with Momentum base of 84/100 and fading Risk resilience at 63/100. Wait for component alignment before adding exposure.
Momentum (84/100) leads while Risk resilience (63/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.40% stock move · HALO classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is HALO Bullish or Bearish Right Now?
HALO currently has a bullish overall setup. Momentum is the strongest factor at 84/100, while Risk Resilience is weakest at 63/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 81/100.
- - Momentum is constructive at 84/100.
- - Technical consensus has more sell votes than buy votes (34 vs 10).
Current Consensus
HALO's Technical Analysis Consensus is currently Strong Sell, with 10 buy, 1 neutral, and 34 sell votes. HALO's 14-day RSI is 26.68, which places the stock in an oversold momentum range. HALO's beta is 0.58, indicating lower market sensitivity than the broad market.
What Changed in HALO?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the HALO Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
HALO Decision Framework
Public evidence layers, setup checks, and risk context for Halozyme Therapeutics, Inc..
Halozyme Therapeutics, Inc. (HALO) Stock Analysis
Halozyme Therapeutics, Inc. has an AIQ Score of 78/100 in a Bullish regime. Momentum is strongest at 84/100. Beta is 0.58, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | HALO is in a Bullish AIQ regime with score 78/100. |
| Signal Conflict | The primary conflict is that momentum leads at 84/100 while risk lags at 63/100. |
| Factor Evidence | Momentum 84/100 · Value 76/100 · Quality 81/100 · Risk 63/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 84/100.
Momentum is 84/100 and RSI (14) is 26.7.
HALO is in a Bullish regime at 78/100.
Risk factor is 63/100 with beta 0.58 and annual volatility 41.04%.
Current conflict: momentum leads at 84/100 while risk lags at 63/100.
HALO Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
HALO Fundamentals
HALO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
HALO Technical Analysis
HALO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
HALO Stock Catalysts
Track HALO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
HALO Dividend Analysis
HALO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
HALO Financial Data
HALO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
HALO Risk Analysis
HALO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
HALO Stock News
HALO stock news, market tone, recent headlines, and catalyst context.
HALO vs Biotechnology Peers
Current peer cohort: HALO · HRMY · IDYA · IMNM. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| HALO Current stock | — | — | — | — | 0.95 | 41.04% | Current |
| HRMY Harmony Biosciences Holdings, Inc. | — | — | — | — | 0.07 | 40.59% | HALO vs HRMY |
| IDYA IDEAYA Biosciences, Inc. | — | — | — | — | 0.14 | 44.94% | HALO vs IDYA |
| IMNM Immunome, Inc. | — | — | — | — | 0.45 | 60.72% | HALO vs IMNM |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for HALO: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalystsNo quarterly financial rows in this snapshot.
Checked —
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Quarterly financial history appears when reported fields are present.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching HALO
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for HALO
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
HALO Stock FAQ
What is HALO stock price today?
Halozyme Therapeutics, Inc.'s current stock price is $100.27. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is HALO bullish or bearish right now?
HALO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is HALO's market cap?
HALO's market cap is $12.56B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is HALO's current P/E ratio?
HALO's current P/E ratio is 23.87 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is HALO's RSI?
HALO's 14-day RSI is 26.68 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is HALO above its 50-day and 200-day moving averages?
HALO is -12.48% from its 50-day SMA and 17.38% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is HALO's next earnings date?
HALO's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does HALO pay a dividend?
HALO's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.